A pharmaceutical company claims its new drug reduces blood pressure in most patients with mild hypertension. The company argues the drug should be adopted.

Study for the Logical Reasoning STEM Test. Practice with flashcards and multiple-choice questions, each with hints and explanations. Prepare for success!

In clinical decision making, whether a drug should be adopted hinges on real patient outcomes, not just intermediate changes. Lowering blood pressure is a surrogate effect; what really matters is whether the treatment lowers the risk of heart events, strokes, or death. If a larger long-term trial shows no reduction in heart events, the drug doesn’t demonstrate a meaningful clinical benefit, so adopting it isn’t justified by the evidence, even though it lowers BP in many patients.

Safety concerns matter too, and substantial side effects in a minority raise valid warnings against use, but they don’t by themselves prove there’s no overall benefit. The finding that BP reduction occurs only in adherent patients suggests limited effectiveness and generalizability, but the decisive issue remains whether hard outcomes improve. Cost differences are relevant for cost-effectiveness, yet they don’t overcome a lack of demonstrated improvement in key health outcomes.